SinoMab BioScience (HKG:3681) agreed to issue a total of 112,810,817 shares to 26 subscribers at HK$1.10 apiece to raise net proceeds of nearly HK$124 million, a Tuesday Hong Kong bourse filing said.
The shares represent around 9.37% of the biopharmaceutical company's enlarged issued share capital.
The firm will use proceeds from the issue for R&D, clinical programs, and potential global cooperations of SM17; diversification of the product portfolio by carrying out research, trials, production, and more for new drug candidates; and general working capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.